Clinical efficacy and safety of intensive atorvastatin therapy in patients with acute coronary syndrome
LI Jing-fang
QI Shu-ying
YANG Xiu-shang
Abstract：Objective To discuss the clinical efficacy and safety of intensive atorvastatin therapy in patients with acute coronary syndrome (ACS). Methods ACS patients (n=70, male 39, female 31, aged from 31 to 88 and average age=55.3±5.9) were chosen from Jan. 2009 to Jan. 2013. All patients were randomly divided into intensive group and control group (n=35), and were given routine therapy. The intensive group was additionally given atorvastatin (20 mg) and control group, 10 mg for 8 w. The changes of high-sensitivity C-reactive protein (hs-CRP), interleukin-10 (IL-10) and matrix metalloproteinase-9 (MMP-9) were detected before and after treatment, clinical efficacy was reviewed and adverse reactions were recorded in 2 groups. Results The levels of hs-CRP and MMP-9 decreased and IL-10 increased in control group and intensive group after treatment (all P<0.05). After treatment, hs-CRP and MMP-9 decreased and IL-10 increased in intensive group compared with control group (all P<0.05). The total effective rate was higher in intensive group than that in control group (88.6%vs. 68.6%, P<0.05). The incidence of adverse reactions had no statistical difference between 2 groups (11.4%vs. 5.7%, P>0.05). Conclusion The intensive atorvastatin therapy has better curative effect and less adverse reactions in the treatment of ACS.
Keywords：AtorvastatinAcute coronary syndromeSafetyClinical efficacy
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 326-327,330 )